Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034

Neil P. Shah, Philippe Rousselot, Charles Schiffer, Delphine Rea, Jorge E. Cortes, Jorge Milone, Hesham Mohamed, Diane Healey, Hagop Kantarjian, Andreas Hochhaus, Giuseppe Saglio

Research output: Contribution to journalArticle

Abstract

Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-generation BCR–ABL1 tyrosine kinase inhibitor (TKI). Patients (n = 670) with imatinib-resistant or -intolerant CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a greater proportion in the 100 mg once daily arm remaining on therapy. Seven-year rates for major molecular response (MMR), progression-free survival (PFS), and overall survival (OS) were similar across doses; MMR, PFS, and OS results were 46, 42, and 65% at 100 mg once daily, respectively. Improved PFS and OS rates were reported in patients who achieved BCR–ABL1 ≤10% at 3 and 6 months. No new safety signals were identified. The incidence of drug-related pleural effusion was 28% at 100 mg once daily and 35% at the other three dose groups. Incidence of drug-related pulmonary hypertension and pulmonary arterial hypertension remained low (≤3% across all doses). Arterial ischemic events occurred in ≤4% of patients across all doses. These data support the long-term efficacy and well-established safety profile of dasatinib for patients with imatinib-resistant or -intolerant CML in chronic phase. Am. J. Hematol. 91:869–874, 2016.

Original languageEnglish (US)
Pages (from-to)869-874
Number of pages6
JournalAmerican Journal of Hematology
Volume91
Issue number9
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Disease-Free Survival
Pulmonary Hypertension
Safety
Survival
Incidence
Pleural Effusion
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Imatinib Mesylate
Dasatinib
Survival Rate
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients : 7-year follow-up of study CA180-034. / Shah, Neil P.; Rousselot, Philippe; Schiffer, Charles; Rea, Delphine; Cortes, Jorge E.; Milone, Jorge; Mohamed, Hesham; Healey, Diane; Kantarjian, Hagop; Hochhaus, Andreas; Saglio, Giuseppe.

In: American Journal of Hematology, Vol. 91, No. 9, 01.09.2016, p. 869-874.

Research output: Contribution to journalArticle

Shah, NP, Rousselot, P, Schiffer, C, Rea, D, Cortes, JE, Milone, J, Mohamed, H, Healey, D, Kantarjian, H, Hochhaus, A & Saglio, G 2016, 'Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034', American Journal of Hematology, vol. 91, no. 9, pp. 869-874. https://doi.org/10.1002/ajh.24423
Shah, Neil P. ; Rousselot, Philippe ; Schiffer, Charles ; Rea, Delphine ; Cortes, Jorge E. ; Milone, Jorge ; Mohamed, Hesham ; Healey, Diane ; Kantarjian, Hagop ; Hochhaus, Andreas ; Saglio, Giuseppe. / Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients : 7-year follow-up of study CA180-034. In: American Journal of Hematology. 2016 ; Vol. 91, No. 9. pp. 869-874.
@article{25f8e0abdc234265be2cb359f4a5ebc6,
title = "Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034",
abstract = "Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-generation BCR–ABL1 tyrosine kinase inhibitor (TKI). Patients (n = 670) with imatinib-resistant or -intolerant CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a greater proportion in the 100 mg once daily arm remaining on therapy. Seven-year rates for major molecular response (MMR), progression-free survival (PFS), and overall survival (OS) were similar across doses; MMR, PFS, and OS results were 46, 42, and 65{\%} at 100 mg once daily, respectively. Improved PFS and OS rates were reported in patients who achieved BCR–ABL1 ≤10{\%} at 3 and 6 months. No new safety signals were identified. The incidence of drug-related pleural effusion was 28{\%} at 100 mg once daily and 35{\%} at the other three dose groups. Incidence of drug-related pulmonary hypertension and pulmonary arterial hypertension remained low (≤3{\%} across all doses). Arterial ischemic events occurred in ≤4{\%} of patients across all doses. These data support the long-term efficacy and well-established safety profile of dasatinib for patients with imatinib-resistant or -intolerant CML in chronic phase. Am. J. Hematol. 91:869–874, 2016.",
author = "Shah, {Neil P.} and Philippe Rousselot and Charles Schiffer and Delphine Rea and Cortes, {Jorge E.} and Jorge Milone and Hesham Mohamed and Diane Healey and Hagop Kantarjian and Andreas Hochhaus and Giuseppe Saglio",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/ajh.24423",
language = "English (US)",
volume = "91",
pages = "869--874",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients

T2 - 7-year follow-up of study CA180-034

AU - Shah, Neil P.

AU - Rousselot, Philippe

AU - Schiffer, Charles

AU - Rea, Delphine

AU - Cortes, Jorge E.

AU - Milone, Jorge

AU - Mohamed, Hesham

AU - Healey, Diane

AU - Kantarjian, Hagop

AU - Hochhaus, Andreas

AU - Saglio, Giuseppe

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-generation BCR–ABL1 tyrosine kinase inhibitor (TKI). Patients (n = 670) with imatinib-resistant or -intolerant CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a greater proportion in the 100 mg once daily arm remaining on therapy. Seven-year rates for major molecular response (MMR), progression-free survival (PFS), and overall survival (OS) were similar across doses; MMR, PFS, and OS results were 46, 42, and 65% at 100 mg once daily, respectively. Improved PFS and OS rates were reported in patients who achieved BCR–ABL1 ≤10% at 3 and 6 months. No new safety signals were identified. The incidence of drug-related pleural effusion was 28% at 100 mg once daily and 35% at the other three dose groups. Incidence of drug-related pulmonary hypertension and pulmonary arterial hypertension remained low (≤3% across all doses). Arterial ischemic events occurred in ≤4% of patients across all doses. These data support the long-term efficacy and well-established safety profile of dasatinib for patients with imatinib-resistant or -intolerant CML in chronic phase. Am. J. Hematol. 91:869–874, 2016.

AB - Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-generation BCR–ABL1 tyrosine kinase inhibitor (TKI). Patients (n = 670) with imatinib-resistant or -intolerant CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a greater proportion in the 100 mg once daily arm remaining on therapy. Seven-year rates for major molecular response (MMR), progression-free survival (PFS), and overall survival (OS) were similar across doses; MMR, PFS, and OS results were 46, 42, and 65% at 100 mg once daily, respectively. Improved PFS and OS rates were reported in patients who achieved BCR–ABL1 ≤10% at 3 and 6 months. No new safety signals were identified. The incidence of drug-related pleural effusion was 28% at 100 mg once daily and 35% at the other three dose groups. Incidence of drug-related pulmonary hypertension and pulmonary arterial hypertension remained low (≤3% across all doses). Arterial ischemic events occurred in ≤4% of patients across all doses. These data support the long-term efficacy and well-established safety profile of dasatinib for patients with imatinib-resistant or -intolerant CML in chronic phase. Am. J. Hematol. 91:869–874, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84983070734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983070734&partnerID=8YFLogxK

U2 - 10.1002/ajh.24423

DO - 10.1002/ajh.24423

M3 - Article

C2 - 27192969

AN - SCOPUS:84983070734

VL - 91

SP - 869

EP - 874

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -